European Innovation Council

Sequentia Biotech, founded in 2013 by Walter Sanseverino and Riccardo Aiese Cigliano, is a bioinformatics company based at the UAB Research Park. The company specializes in transforming genomic data into actionable insights for various sectors, including academic research, plant and animal breeding, and biomedicine. Sequentia collaborates with over 30 public and private research centers, universities, and companies, participating in more than 160 research and development projects. The company offers a range of services, including cloud software, custom software solutions, and bioinformatics consulting, aimed at advancing healthcare, agriculture, and environmental sciences. Sequentia Biotech also maintains two open-source biodata banks and has developed an award-winning research initiative called Tricopharming. The founders have contributed significantly to the field, with over 40 scientific publications in prestigious journals.

Epigene Labs SAS, founded in 2019 and headquartered in Paris, France, with an additional office in Boston, Massachusetts, develops a biotechnology platform that harnesses advanced artificial intelligence to transform genomic data into actionable insights for precision oncology. The platform addresses the challenges of aggregating, analyzing, and visualizing extensive genomic datasets, which are crucial for advancing precision oncology. By integrating proprietary data from partners with publicly available information, Epigene Labs provides medical researchers with user-friendly analytics and insights that facilitate drug development and research in cancer treatment. The company focuses on forming value-based partnerships with leading cancer centers and prominent biotech firms to enhance the efficacy of oncology solutions.

Genomika Lietuva is a business that provides cutting-edge, perceptive, and meticulously optimized solutions for the biomedical sciences. It creates DNA storage technologies that allow for high-density storage of significant amounts of information in a remarkably tiny area.

Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that provide a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, particularly in the field of transcriptomics. Scipio Bioscience's innovative products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating advanced analysis and research in the life sciences.

Arthex Biotech S.L. is a biotechnology company based in Paterna, Spain, that specializes in the development of antisense RNA therapies for genetic diseases. Founded in 2019 as a spin-off from the University of Valencia, the company focuses on addressing unmet medical needs through innovative treatments targeting microRNAs, which are implicated in various disorders, including neuromuscular diseases. With a team experienced in drug discovery and strong support from leading scientific and clinical advisors, Arthex Biotech aims to provide effective therapies for patients suffering from rare and challenging conditions.

Samplix is a biotechnology company based in Herlev, Denmark, focused on single-molecule sample preparation for DNA and RNA. It has developed the Xdrop™ technology, which utilizes a unique “water-oil-water” droplet system to create millions of reaction chambers for handling individual DNA molecules. This innovative approach allows for targeted enrichment of large DNA fragments and enables researchers to sequence specific genetic regions effectively. Samplix's technology addresses the limitations of existing multi-molecule preparation methods, providing enhanced precision and sensitivity while simplifying the sample preparation process. Its solutions empower scientists to make informed research decisions, particularly in applications related to virus integration and CRISPR editing.

Samplix is a biotechnology company based in Herlev, Denmark, focused on single-molecule sample preparation for DNA and RNA. It has developed the Xdrop™ technology, which utilizes a unique “water-oil-water” droplet system to create millions of reaction chambers for handling individual DNA molecules. This innovative approach allows for targeted enrichment of large DNA fragments and enables researchers to sequence specific genetic regions effectively. Samplix's technology addresses the limitations of existing multi-molecule preparation methods, providing enhanced precision and sensitivity while simplifying the sample preparation process. Its solutions empower scientists to make informed research decisions, particularly in applications related to virus integration and CRISPR editing.

Inbiome is a biotechnology company specializing in molecular diagnostics. It has developed proprietary molecular culture technology that accelerates bacterial testing and microbiome analysis. The company aims to advance clinical microbiology by focusing on microbial detection and product development, enabling more accurate and timely diagnoses, and ultimately improving patient outcomes.

Arctic Therapeutics is a drug discovery and development company focused on identifying the genetic underpinnings of various diseases, both rare and common. Utilizing bioinformatic approaches and artificial intelligence, the company aims to mitigate the significant risks and high costs associated with traditional drug development, thereby accelerating the process of bringing effective treatments to patients. Collaborating with The Center for Applied Genomics at the Children’s Hospital of Philadelphia, Arctic Therapeutics is engaged in repurposing and developing innovative medical treatments. The company’s pipeline, which includes a promising Alzheimer's drug candidate, is conservatively valued at over $100 billion, with the potential not only to treat dementia but also to prevent it. Arctic Therapeutics was founded by Dr. Hakon Hakonarson, a leading figure in applied genomics, known for his substantial contributions to the field, including the establishment of the largest pediatric biobank and genomic database globally. Dr. Hakonarson has received significant recognition for his research, which includes breakthroughs in autism genetics and precision-based therapies.

Arctic Therapeutics is a drug discovery and development company focused on identifying the genetic underpinnings of various diseases, both rare and common. Utilizing bioinformatic approaches and artificial intelligence, the company aims to mitigate the significant risks and high costs associated with traditional drug development, thereby accelerating the process of bringing effective treatments to patients. Collaborating with The Center for Applied Genomics at the Children’s Hospital of Philadelphia, Arctic Therapeutics is engaged in repurposing and developing innovative medical treatments. The company’s pipeline, which includes a promising Alzheimer's drug candidate, is conservatively valued at over $100 billion, with the potential not only to treat dementia but also to prevent it. Arctic Therapeutics was founded by Dr. Hakon Hakonarson, a leading figure in applied genomics, known for his substantial contributions to the field, including the establishment of the largest pediatric biobank and genomic database globally. Dr. Hakonarson has received significant recognition for his research, which includes breakthroughs in autism genetics and precision-based therapies.

Enduro Genetics is a technology provider that specializes in enhancing large-scale fermentations through its proprietary synthetic biology technology. The company focuses on improving the performance of fermentation processes by developing a genetic plugin technology that is free of antibiotic resistance genes. This innovation allows for higher yields by enriching spontaneous high producers within the fermentation population, facilitating the production of complex or cellular inhibit products by addressing strain instability. By maximizing the performance of cells derived from production strains, Enduro aims to bolster the competitiveness of both current and future green bioproduction initiatives.

VIVAN Therapeutics is a company focused on transforming cancer care through personalized therapeutics. It utilizes a novel assay technology licensed from the Center for Personalized Cancer Therapeutics at Mt Sinai New York, which enables the development of tailored treatment strategies. The company's approach involves the Personal Discovery Process (PDP), a unique clinical trial method designed for individual patients. This process analyzes the genetic complexity of each patient's tumor by engineering it into fruit flies, allowing for the evaluation of both FDA-approved cancer and non-cancer drugs. VIVAN Therapeutics aims to provide less toxic and more affordable treatment options by recommending combinations of these drugs, thereby enhancing the effectiveness of cancer therapies. The company is also working on new diagnostics and decision support tools to improve treatment outcomes for cancer patients.

Arthex Biotech S.L. is a biotechnology company based in Paterna, Spain, that specializes in the development of antisense RNA therapies for genetic diseases. Founded in 2019 as a spin-off from the University of Valencia, the company focuses on addressing unmet medical needs through innovative treatments targeting microRNAs, which are implicated in various disorders, including neuromuscular diseases. With a team experienced in drug discovery and strong support from leading scientific and clinical advisors, Arthex Biotech aims to provide effective therapies for patients suffering from rare and challenging conditions.

Arthex Biotech S.L. is a biotechnology company based in Paterna, Spain, that specializes in the development of antisense RNA therapies for genetic diseases. Founded in 2019 as a spin-off from the University of Valencia, the company focuses on addressing unmet medical needs through innovative treatments targeting microRNAs, which are implicated in various disorders, including neuromuscular diseases. With a team experienced in drug discovery and strong support from leading scientific and clinical advisors, Arthex Biotech aims to provide effective therapies for patients suffering from rare and challenging conditions.

Core Biogenesis is a biotechnology company based in Paris, France, established in 2020. It specializes in next-generation recombinant protein production technologies, utilizing proprietary gene editing and plant biotechnology to significantly lower the costs associated with producing growth factors. These growth factors are crucial for applications in the clean meat and cell therapy industries. The company has developed an ultra-scalable bioproduction platform that leverages plants as biofactories, enabling efficient mass production and targeted extraction of valuable bioproducts. This innovative approach not only accelerates production but also enhances the ability to regulate cell growth and increases yields, making it a valuable partner for clients in the healthcare sector.

NeuoKaire, previously known as Genetika+, is focused on advancing personalized medical testing for the treatment of depression. The company has developed a platform that utilizes biological, medical, and genetic data, along with innovative technology, to identify the most effective drug therapies for individual patients. This approach aims to facilitate faster treatment, minimize side effects, and reduce dosages. By assisting pharmaceutical companies in differentiating their products and de-risking clinical trials, NeuoKaire enhances the identification of responsive patients and improves stratification. The integration of stem-cell technology, genomics, and artificial intelligence further supports the optimization of treatments for psychiatric and neurological disorders, ultimately aiming to transform care and improve patient outcomes.

Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that provide a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, particularly in the field of transcriptomics. Scipio Bioscience's innovative products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating advanced analysis and research in the life sciences.

Core Biogenesis is a biotechnology company based in Paris, France, established in 2020. It specializes in next-generation recombinant protein production technologies, utilizing proprietary gene editing and plant biotechnology to significantly lower the costs associated with producing growth factors. These growth factors are crucial for applications in the clean meat and cell therapy industries. The company has developed an ultra-scalable bioproduction platform that leverages plants as biofactories, enabling efficient mass production and targeted extraction of valuable bioproducts. This innovative approach not only accelerates production but also enhances the ability to regulate cell growth and increases yields, making it a valuable partner for clients in the healthcare sector.

Computomics GmbH is a bioinformatics company based in Tübingen, Germany, specializing in molecular data analysis for crop biotechnology and agricultural research. Founded in 2012, the company offers a range of services, including the analysis of large, polyploid plant genomes, transcriptome studies, differential gene expression, and functional genome annotation. It also provides reference-free genotyping, DNA methylation analysis, and metagenomic analysis. By applying advanced machine learning models to biological data, Computomics helps researchers accelerate genetic gains and make informed decisions in over 190 projects. The company's goal is to support sustainable agricultural development, enabling clients in agriculture, biotechnology, microbiome research, and metabolomics to derive actionable insights from their genomic data.

Core Biogenesis is a biotechnology company based in Paris, France, established in 2020. It specializes in next-generation recombinant protein production technologies, utilizing proprietary gene editing and plant biotechnology to significantly lower the costs associated with producing growth factors. These growth factors are crucial for applications in the clean meat and cell therapy industries. The company has developed an ultra-scalable bioproduction platform that leverages plants as biofactories, enabling efficient mass production and targeted extraction of valuable bioproducts. This innovative approach not only accelerates production but also enhances the ability to regulate cell growth and increases yields, making it a valuable partner for clients in the healthcare sector.

Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that provide a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, particularly in the field of transcriptomics. Scipio Bioscience's innovative products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating advanced analysis and research in the life sciences.

Computomics GmbH is a bioinformatics company based in Tübingen, Germany, specializing in molecular data analysis for crop biotechnology and agricultural research. Founded in 2012, the company offers a range of services, including the analysis of large, polyploid plant genomes, transcriptome studies, differential gene expression, and functional genome annotation. It also provides reference-free genotyping, DNA methylation analysis, and metagenomic analysis. By applying advanced machine learning models to biological data, Computomics helps researchers accelerate genetic gains and make informed decisions in over 190 projects. The company's goal is to support sustainable agricultural development, enabling clients in agriculture, biotechnology, microbiome research, and metabolomics to derive actionable insights from their genomic data.

enGenome is a bioinformatics company that specializes in genomic interpretation and the development of software aimed at diagnosing genetic diseases. By providing accurate omics-based reports to physicians, enGenome improves the processes of diagnosis and treatment for patients. Their platform automates the interpretation of genetic variants, reduces the occurrence of variants of uncertain significance (VUS), and reports supporting evidence, allowing geneticists to identify pathogenic genomic variants efficiently and accurately. This focus on precision aids in enhancing the overall quality of healthcare for individuals with genetic conditions.

Sequentia Biotech, founded in 2013 by Walter Sanseverino and Riccardo Aiese Cigliano, is a bioinformatics company based at the UAB Research Park. The company specializes in transforming genomic data into actionable insights for various sectors, including academic research, plant and animal breeding, and biomedicine. Sequentia collaborates with over 30 public and private research centers, universities, and companies, participating in more than 160 research and development projects. The company offers a range of services, including cloud software, custom software solutions, and bioinformatics consulting, aimed at advancing healthcare, agriculture, and environmental sciences. Sequentia Biotech also maintains two open-source biodata banks and has developed an award-winning research initiative called Tricopharming. The founders have contributed significantly to the field, with over 40 scientific publications in prestigious journals.

Genome Biologics specializes in therapeutic target discovery and RNA-targeted therapies, focusing on cardiovascular and cardiometabolic diseases. The company employs an innovative biotherapeutics platform that integrates AI-based machine learning with advanced single-cell transgenesis techniques to enhance drug development. This approach allows for the identification of new compounds and the repurposing of existing drugs, ultimately facilitating more efficient and ethical preclinical research. By addressing conditions where traditional treatments are ineffective or nonexistent, Genome Biologics aims to reduce the cost and duration of drug development while minimizing the ethical challenges associated with medical research.

Sequentia Biotech, founded in 2013 by Walter Sanseverino and Riccardo Aiese Cigliano, is a bioinformatics company based at the UAB Research Park. The company specializes in transforming genomic data into actionable insights for various sectors, including academic research, plant and animal breeding, and biomedicine. Sequentia collaborates with over 30 public and private research centers, universities, and companies, participating in more than 160 research and development projects. The company offers a range of services, including cloud software, custom software solutions, and bioinformatics consulting, aimed at advancing healthcare, agriculture, and environmental sciences. Sequentia Biotech also maintains two open-source biodata banks and has developed an award-winning research initiative called Tricopharming. The founders have contributed significantly to the field, with over 40 scientific publications in prestigious journals.

Epigene Labs SAS, founded in 2019 and headquartered in Paris, France, with an additional office in Boston, Massachusetts, develops a biotechnology platform that harnesses advanced artificial intelligence to transform genomic data into actionable insights for precision oncology. The platform addresses the challenges of aggregating, analyzing, and visualizing extensive genomic datasets, which are crucial for advancing precision oncology. By integrating proprietary data from partners with publicly available information, Epigene Labs provides medical researchers with user-friendly analytics and insights that facilitate drug development and research in cancer treatment. The company focuses on forming value-based partnerships with leading cancer centers and prominent biotech firms to enhance the efficacy of oncology solutions.

Developer of microbiome analysis technology designed to monitor the microbiome status and function and quantify its impact on all aspects of human life. The company's technology simplifies, accelerates, and democratizes microbiome analysis to precisely measure the composition and dynamics of the microbiome by uncovering its role in human health and the environment, enabling researchers to access genetic analysis devices to analyze the full genetic makeup of microbiomes.

Developer of microbiome analysis technology designed to monitor the microbiome status and function and quantify its impact on all aspects of human life. The company's technology simplifies, accelerates, and democratizes microbiome analysis to precisely measure the composition and dynamics of the microbiome by uncovering its role in human health and the environment, enabling researchers to access genetic analysis devices to analyze the full genetic makeup of microbiomes.